Related Experiment Video
Updated: Apr 12, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Progressive bevacizumab-associated renal thrombotic microangiopathy
Alice L Uy1, Novae B Simper2, Anne L Champeaux2
1Department of Medicine, Nephrology Service.
Bevacizumab, a VEGF inhibitor, caused progressive kidney damage and nephrotic syndrome in a patient with pre-existing chronic kidney disease. This severe thrombotic microangiopathy (TMA) did not resolve after stopping the drug, highlighting potential risks.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF) is crucial for glomerular filtration barrier integrity.
- Bevacizumab, a VEGF-targeting monoclonal antibody, is used for metastatic solid tumors.
- Chronic kidney disease (CKD) affects renal function and drug metabolism.
Related Concept Videos
Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Venous Thrombosis III: Interprofessional Care
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis I: Introduction
Acute Kidney Injury III: Clinical Manifestations

